SC11: Developability of Bispecific Antibodies: Assays and Case Studies
TUESDAY, September 1 | DINNER, 6:00 – 8:30 PM
ABOUT THIS COURSE:
Bispecific antibodies are a rapidly growing and clinically validated class of antibodies with two marketed drugs and multiple candidates in clinical trials. Targeting multiple antigens in a synergistic manner can confer enhanced therapeutic benefit and
potentially uncover novel biological mechanisms. However, multiple formats and a tedious candidate selection process to select functional and developable bispecific antibodies makes such programs cumbersome. This short course focuses on challenges
with discovery and development of bispecific antibodies. We will review in detail the various assays that could be utilized to assess developability of bispecific antibodies. In addition, we will use an approved bispecific antibody as a case study
to understand the varied aspects of discovery and development of bispecific antibody programs.
WHAT YOU WILL LEARN:
- What is developability and why should you consider it for your therapeutic antibody programs
- Assays for early and late stage developability assessment of antibodies
- How to select for or engineer desirable developability features in your bispecific antibodies
COURSE AGENDA:
6:00 pm Introduction to Bispecific Antibodies and Developability
Nimish Gera, PhD, Head, Biologics, Mythic Therapeutics
This module will briefly review the challenges with development of a bispecific antibody over a monospecific antibody and the need for developability assessments.
6:30 Dinner Break
7:00 Early Stage Developability Assays
Nimish Gera, PhD, Head, Biologics, Mythic Therapeutics
Favorable developability attributes can be selected for early in the antibody discovery process and this module will highlight features that increase the chances of late stage success
7:30 Late Stage Developability Assays
Nimish Gera, PhD, Head, Biologics, Mythic Therapeutics
Biology can dictate the early discovery process and this module highlights the late stage developability assays to optimize the selected candidate(s) for development.
8:00 Case study of an approved Bispecific Antibody
Nimish Gera, PhD, Head, Biologics, Mythic Therapeutics
This module discusses the discovery and development of an approved bispecific antibody as a case study to underscore the importance of developability in antibody programs.
8:30 Close of Course
INSTRUCTOR BIOGRAPHY:
Nimish Gera, PhD, Head, Biologics, Mythic Therapeutics
Nimish Gera is the Head of Biologics at Mythic Therapeutics, leading multiple programs to engineer and develop novel antibody and antibody-based drugs in oncology and immuno-oncology. Prior to Mythic, Nimish has over ten years of
experience in antibody and protein engineering with five years leading bispecific antibody programs in several disease areas such as rare diseases, oncology and immunology at Alexion Pharmaceuticals and Oncobiologics. Nimish received his PhD degree
in Chemical and Biomolecular Engineering from North Carolina State University and a B.Tech degree in Chemical Engineering from Indian Institute of Technology, Guwahati.